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ABSTRACT 
Lipids play an essential role within the heart as they are involved in energy storage, 
membrane stability and signaling. Changes in cardiac lipid composition and utilization 
may thus have profound effects on cardiac function. Importantly, the diseased heart is 
associated with intracellular metabolic abnormalities, including accumulation of 
lipids. In this thesis, I targeted cardiac lipid droplets (LDs) and membrane lipids using 
genetically modified mice and cultured cardiomyocytes to investigate how myocardial 
lipid content and composition affect cardiac function.  
In Paper I, we investigated the LD protein perilipin 2 (Plin2) and its role in myocardial 
lipid storage. Unexpectedly, Plin2 deficiency in mice result in increased triglyceride 
levels within the heart as a result of decreased lipophagy. Even though Plin2-/- mice 
had markedly enhanced lipid levels in the heart, they had normal heart function under 
baseline conditions and under mild stress. However, after an induced myocardial 
infarction, cardiac function reduced in Plin2-/- mice compared with Plin2+/+ mice. 
We have previously shown in both humans and mice that low levels of cardiac Plin5 
are unfavorable for heart function. Therefore, in Paper II we tested the hypothesis that 
forced overexpression of cardiac Plin5 is beneficial for heart function. We found that 
Plin5 promotes exercise-like effects, inducing physiological hypertrophy with 
enhanced left ventricular mass, but with preserved heart function. Furthermore, 
calmodulin-dependent protein kinase II (CaMKII) and phospholamban activities were 
increased by Plin5 overexpression, indicating enhanced cardiac contractility and 
calcium handling. 
In Paper III, we found that the sphingolipid glucosylceramide (GlcCer) accumulates 
in the human heart following injury. We targeted cardiac Ugcg (the gene encoding 
GlcCer synthase) in mice (hUgcg–/– mice) and found that a significant decrease in 
GlcCer in cardiomyocytes results in Golgi dispersion and defective autophagy 
regulation, leading to compromised β-adrenergic signaling. hUgcg–/– mice developed 
dilated cardiomyopathy and died prematurely from heart failure.  
In conclusion, our studies show that dysfunctional cardiac lipid storage plays a role in 
heart function, both in the healthy and diseased heart. Thus, targeting cardiac lipid 
accumulation may be a future strategy to delay cardiovascular disease progression.  
 
Keywords: Cardiovascular disease, Lipid droplets, Perilipins, Lipid accumulation, 
Metabolism, GlcCer. 
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 SAMMANFATTNING PÅ SVENSKA 
Hjärtsjukdom är den vanligaste orsaken till sjuklighet och dödlighet i 
världen. Trots förbättrad behandling av hjärtinfarkt, högt blodtryck och 
klaffsjukdom så utvecklar fortfarande en stor del av de överlevande 
patienterna hjärtsvikt. Forskning kring nya behandlingsformer för 
hjärtsjukdom är därför ytterst relevant.  
 
Vid hjärtsjukdom så sker en så kallad remodellering av hjärtat, där 
vänsterkammaren genomgår form- och volymförändringar. Detta är en 
omedelbar kompensation för att öka hjärtkontraktiliteten akut men leder 
i förlängningen till försämrad pumpfunktion och hjärtsvikt.  
Remodellering av hjärtat är också kopplat till en metabol adaptation där 
kardiomyocyterna ställer om från att främst använda sig av lipider som 
substrat till att förlita sig på glukos, vilket i sin tur leder till ökad 
inlagring av lipid i hjärtat. Lipid lagras i hjärtats celler i så kallade 
lipiddroppar, främst i form av neutrala fetter (som kolesterolestrar och 
triglycerider). Lipiddropparnas lagringsförmåga regleras av 
lipiddroppsproteiner, framförallt perilipiner (Plin). Vid hjärtsjukdom 
ökar de neutrala lipiderna men också inlagring av lipider som sitter i 
kardiomyocyternas membran, t.ex. sfingolipider. Lipidinlagring i hjärtat 
är kopplat till försämrad hjärtfunktion. Dock finns det fortfarande 
mycket liten kunskap om hur och varför lipidinlagring egentligen skadar 
hjärtat. I denna avhandling har vi studerat sambandet mellan hjärtats 
lipidlagring och hjärtfunktion, både i det friska hjärtat och vid sjukdom.  
 
Delarbete I. I denna studie har vi undersökt om Perilipin 2 (Plin2) är 
involverad i lipidinlagring och påverkar hjärtfunktionen. Avsaknad av 
Plin2 i möss ledde paradoxalt nog till ökade nivåer av lipid i hjärtat, som 
ett resultat av minskad lipofagi. Trots att mössen som saknar Plin2 har 
nästan dubbelt så mycket inlagrad lipid i hjärtat så har de basalt en 
normal hjärtfunktion.  
 
 
Delarbete II. Eftersom vi tidigare har visat hos både människor och 
möss att det är negativt för hjärtfunktionen att ha låga nivåer av Plin5, 
så undersökte vi i delarbete II hur hjärtat påverkas av ökade nivåer av 
Plin5. Ökat uttryck av Plin5 leder till fysiologisk hypertrofi i hjärtat, 
liknande den som induceras av fysisk aktivitet, och resulterar i en 
skyddande hjärtfunktion. 
 
Delarbete III. I detta arbete studerade vi inlagringen av sfingolipiden 
glucosylceramid i hjärtat och vilken funktion denna lipid har i 
kardiomyocyter. Vi fann att kraftigt minskade nivåer av 
glucosylceramider leder till dilaterad kardiomyopati och prematur död 
hos möss, vilket visar att denna sfingolipid har en viktig funktion för 
hjärtats normala fysiologi. 
 
Slutsatsen från våra studier är att en dysfunktionell reglering av 
lipidlagring och hur lipider används av hjärtat påverkar hjärtfunktionen 
både i det friska hjärtat och vid hjärtsjukdom.
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INTRODUCTION 
Cardiovascular diseases (CVDs) is the main cause of morbidity and 
mortality in the world. In spite of improved treatment strategies for 
myocardial infarction (MI), hypertension and valve diseases, a large 
proportion of surviving patients are still developing heart failure (HF) 
with time. Research involving new treatment strategies for CVDs are 
therefore utterly crucial [1, 2].  
 
Remodeling of the heart is occurring in response to pathological injury, 
that results in a change in shape and volume of the left ventricle (LV). 
This is an immediate compensation to increased cardiac contractility, 
but over time it will result in a decreased pump function and HF [3-5]. 
Remodeling of the heart is also associated with metabolic adaptations, 
the cardiomyocytes switch from using lipids as the main source for 
energy to rely on glucose instead. This will result in an increased 
accumulation of lipids in the heart [6-8]. Lipids are stored in the 
cardiomyocytes in organelles called lipid droplets (LDs), primarily in 
the form of neutral lipids (cholesterol esters and triglycerides). The LDs 
storage ability is regulated by LD proteins, mainly the perilipin (Plin) 
family [9-12]. In response to cardiac diseases neutral lipids are 
increasing and lipids that are located in the membranes of the 
cardiomyocytes are accumulating, e.g. sphingolipids. Lipid 
accumulation in the heart is associated with a decreased heart function 
[13, 14]. However, there is still very little knowledge about how and 
why lipid accumulation in the heart is detrimental. In this thesis, we have 
studied the correlation between lipid accumulation in the heart and heart 
function, both in the healthy and diseased heart.   
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1.1 CARDIOVASCULAR SYSTEM 
The heart is the powerhouse of the body that pumps blood through both 
arteries and veins called the cardiovascular system. The heart is 
constructed of 4 chambers, left and right atrium and left and right 
ventricle. With each heartbeat is oxygen-poor blood flowing in from the 
systemic circulation to the right atrium and then further down to the right 
ventricle where it is pumped out to the lung through the pulmonary vein 
to receive oxygen. From the lung, the oxygen-rich blood flows back into 
the left atrium and then to the left ventricle were it is being pumped out 
to the systemic circulation that will supply the rest of the body with the 
oxygenated blood [15]. The heart itself is supplied with blood from the 
epicardial coronary arteries surrounding the heart. The left coronary 
artery supplies the left artery, ventricle and interventricular septum (the 
wall separating left and right ventricle), while the right coronary artery 
supplies the right atrium, ventricle and the heart’s conduction system 
that regulates contraction of the heart [16, 17].  
 
The left ventricle (LV) ejects approximately 70 ml blood during each 
heart beat defined as stroke volume (SV), and about 5 litres per minute, 
known as cardiac output (CO). CO is calculated through SV times heart 
rate (HR). Cardiac contraction or heart rate is initiated and controlled by 
electrical impulses that are being produced and directed by specialized 
cardiac cells in different regions of the heart. The activation begins in 
the sinoatrial (SA) node, consisting of a band of spontaneous de-
polarizing cells in the right atrium. The rate in the SA node is more rapid 
than in any other region of the heart, and is referred as the pacemaker of 
the heart. As the impulse spreads to the other regions, it causes the cells 
to excite.  
 
The heart rate which is normally around 80 beats/min is regulated by the 
SA node that is further controlled by hormones and nerve impulses. 
More specifically, it is the autonomic nervous system (ANS) that 
regulates this machinery and consists of the sympathetic and 
parasympathetic system that works together [18, 19]. The 
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parasympathetic system is regulated through the vagus nerve that forms 
synapses with cells in the SA node. When the neurotransmitter 
acetylcholine (ACh) is released and binds in to muscarinic acetylcholine 
receptors, more specifically M2 receptors on the cardiac cells within the 
SA node, a decrease in HR referred as a negative chronotropic effect is 
induced. The sympathetic system regulates through postganglionic 
fibres that innervate the SA node. The fibres release noradrenaline (NA) 
that act on β1-adrenergic receptors (β1-AR) on the cells that increase the 
HR, referred as a positive chronotropic effect. The parasympathetic 
response on the SA node controls during normal conditions to give a 
normal HR. An increase in HR is fine-tuned by the sympathetic system 
that is commonly known as the “fight or flight” response and dominates 
during exercise, stress and emergency situations [20, 21].  
 
The cardiac cycle consists of two phases, the diastolic phase which is 
when the heart is relaxing and the heart is filling up with blood, and the 
systolic phase which is when the heart is contracting and ejecting the 
blood out to the body [21, 22]. The contracting cells are the cardiac 
muscle cells, so called cardiomyocytes, that make up 75% of the heart. 
Additional cell types includes smooth muscle cells, endothelial cells of 
the coronary vasculature, fibroblasts and other connective tissue cells 
[23].  
1.1.1 Β-ADRENERGIC RECEPTOR SIGNALING 
The cardiomyocytes which are the contracting cells within the heart are 
mainly regulated by the β-adrenergic receptors (β-AR) that belongs to 
the family of G-protein coupled receptors (GPCRs). β-AR activation 
controls HR and contraction of the heart [24].  The human heart express 
two classes of adrenergic receptors, the α-adrenergic and β-adrenergic 
receptors. They are further divided into nine subgroups with β1-ARs 
being the predominant subgroup of the heart [25, 26]. β-ARs are 
connected to G proteins and during stimulation with catecholamines 
(adrenaline and noradrenaline), a conformational change of the G 
proteins is induced. This results in a dissociation of the G protein into 
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subunit components that act as signalling units. This starts a cascade 
causing an accumulation of the second messenger cyclic adenosine 
monophosphate (cAMP) that binds into protein kinase A (PKA). The 
kinase then phosphorylates a number of proteins affecting contractility 
[24, 27]. PKA specifically targets β-ARs themselves, troponin I, 
phospholamban (PLB) and sarcoplasmic reticular Ca+/ATPase 
inhibitory proteins, all involved in the regulation of cardiac contraction 
[28].  
 
Phosphorylation of β-ARs causes an uncoupling and downregulation of 
the receptor. The uncoupling of the receptor from the G protein induces 
internalization of the receptor. The receptor shifts from being on the 
plasma membrane into cytosolic compartments which is essential to 
keep a balance between activation and deactivation for normal cellular 
homeostasis [28, 29]. The diseased heart, such as during HF is 
characterized by a hyperactivation of the sympatic nervous system 
leading to an increase of circulating catecholamines as a compensatory 
response to maintain a normal CO. However, this chronic stimulation is 
damaging and causing dysfunction in the signalling pathway.  β1-ARs 
undergo downregulation and uncoupling from G proteins making the 
receptors desensitized. The degree of downregulation and 
desensitization is linked to the severity of the HF which further can 
impair heart function causing a vicious outcome [24, 27, 28].  
 
1.2 CARDIOVASCULAR DISEASES 
Despite the progress in cardiology, CVDs remain the most common 
cause of death and morbidity in the industrialized world. The increase 
of major risk factors such as diabetes, hypertension and obesity 
combined with a growing population that live longer, additionally 
increases the burden of CVDs [30-32]. CVDs consists of different types 
of diseases including myocardial infarction (MI), cardiomyopathy, heart 
arrhythmias, artery diseases and HF amongst others [2]. More patients 
are surviving and live longer after a myocardial event today, resulting in 
a higher incidents of patients developing HF. This phenomenon occurs 
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due to complex cellular and molecular changes called ventricular 
remodelling [4, 33]. A major factor contributing to HF is that the human 
heart has very little regenerative capacity with a renewal rate of 0,5-1 % 
per year of the cardiomyocytes. The low rate of cardiomyocyte turnover 
is not enough to compensate for the major loss of cells after an injury 
such as a MI can induce [34].  
1.2.1 CARDIAC REMODELING IN THE DISEASED 
HEART 
In response to a myocardial event such as a MI, the heart is undergoing 
remodeling to compensate for the loss of contractile function in the 
injured area. This is shown as molecular and cellular changes identified 
as alterations in size, mass, geometry and function [33]. Early changes 
can be seen within hours to days after an insult. Myocardial cell death, 
so called necrosis results in an infiltration of inflammatory cells such as 
neutrophils and macrophages [35]. These cells start to break down 
collagen resulting in a thinning and dilation of the area of injury. 
Simultaneously fibroblasts are arriving and start to produce new 
collagen contributing to scar formation. Over the following weeks and 
months, the cardiomyocytes in the non-injured area are becoming 
hypertrophic as a response to the increased work-load in the heart 
resulting in a dilation of the LV. This progression is initially beneficial 
and aimed to maintain a normal CO. Unfortunately, over time are these 
changes resulting in a further increased LV size, that causes more wall 
stress and further dilation and ultimately HF (Figure 1) [4, 33, 36]. 
There are also several molecular changes that are induced that indicates 
that the remodeling process is ongoing in the diseased heart. In 
particular, reactivation of the fetal gene program that is silenced in the 
normal adult healthy heart. This is shown as alterations in the expression 
of myosin heavy chain (MHC) isoforms, with a decrease in α- and an 
increase in β-MHC inducing a slower contraction [37]. Increased 
expression of GLUT-1, reflecting a changed substrate utilization in the 
diseased heart and increased expression of myocardial stretch markers 
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atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are 
detected [3, 4].  
 
Figure 1. Schematic overview of remodeling in the diseased heart.  
 
Cardiac hypertrophy which is the increase in heart mass is considered to 
be a bad prognostic sign associated with many forms of HF [38]. 
Hypertrophy can be divided into two subgroups, pathological 
hypertrophy and physiological hypertrophy. Pathological hypertrophy is 
induced in response to heart diseases. It is a condition where the vital 
cardiomyocytes becomes thicker resulting in a decreased size of the 
chambers and a reduced capacity to pump blood, this to compensate for 
the dead cardiomyocytes and the fibrotic remodelling [38, 39] On the 
contrary, physiological hypertrophy which is seen in athletes, is induced 
by exercise training and can lead to increased cardiomyocyte size. This 
is characterized by normal cardiac morphology with normal or enhanced 
cardiac function completely opposite to pathological hypertrophy [40].  
 
1.3 METABOLIC SUBSTRATE UTILIZATION OF 
THE HEART 
The metabolic demands are the highest for the heart compared to any 
other organ in the body, and a normal cardiac metabolism is needed to 
fuel contractility and vitality. The energy for the heart is dependent on 
sufficient amount of substrates and oxygen to generate adenosine 
triphosphate (ATP) that fuels the heart [7, 41]. There are 3 kinds of 
substrates used for the generation of ATP; Fatty acids (FAs), 
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carbohydrates such as glucose and ketone bodies. FAs are the favoured 
substrate used in the heart and generates most ATP. 
1.3.1 FA UPTAKE AND UTILIZATION 
Long-chain fatty acids (LCFA) are important substrates for the heart, 
but because of their low solubility in water they are provided to the heart 
attached to plasma albumin or bound in triglyceride (TG) core of 
circulating lipoproteins, such as chylomicrons and very-low-density 
lipoproteins (VLDL). These lipoproteins are hydrolysed by lipoprotein 
lipase (LPL) located on epithelial cells of capillaries within the heart [7, 
42]. FAs enter the cardiomyocytes through FA transporters on the cell 
membrane such as CD36/FAT, fatty acid-binding protein (FABP) and 
fatty acid transport protein (FATP). Within the cell, the FAs are 
converted to long-chain acyl-CoA by fatty acyl-CoA synthetase. For the 
long-chain acyl-CoA to be utilized for the generation of ATP, the 
enzyme carnitine palmitodyltransferase 1 (CPT1) is converting it to fatty 
acylcarnitine enabling passage into the mitochondria. Within the 
mitochondria is the fatty acylcarnitine further transported across to the 
inner mitochondrial membrane by carnitine-acylcarnitine translocase 
(CAT). Inside the inner mitochondrial membrane fatty acylcarnitine is 
converted back to fatty acyl-CoA by carnitine palmitodyltransferase 2 
(CPT2) for the utilization during β-oxidation [43]. However, medium-
chain FAs do not require these proteins to enter the mitochondria. Each 
cycle of β-oxidation result in the shortening of the FA by two carbons 
and the production of acyl-CoA, an acetyl-CoA, flavin adenine 
dinucleotide (FADH2) and nicotinamine dinucleotide (NADH). The 
resulting acyl-CoA enters another cycle of β-oxidation, the acetyl-CoA 
enters the tricarboxylic acid cycle (TCA-cycle), and the electron carries 
FADH2 and NADH delivers electrons to the electron transport chain [7, 
44, 45].  
 
The TCA-cycle, also known as the Krebs cycle and citric acid cycle  is 
located in the mitochondrial matrix [46]. This cycle consists of reactions 
used to release stored energy through the oxidation of acetyl-CoA and 
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the generation of NADH and FADH2. The NADH and FADH2 are then 
further fed into the electron transport chain that contains four complexes 
that creates a proton gradient. This gradient facilitates the generation of  
12 adenosine triphosphates (ATPs) and carbon dioxide (CO2) through 
oxidative phosphorylation  by ATP synthase, used to fuel the heart [47].   
1.3.2 ROLE OF MITOCHONDRIA WITHIN THE HEART  
Within the cardiomyocytes are mitochondria occupying one third of the 
cell volume to cope with the high energy demand of the heart [48]. 
Mitochondrial fusion and fission is a constant ongoing process which is 
essential for the maintenance of normal function, and depends on the 
metabolic needs of the cardiomyocytes [49, 50]. Fusion of mitochondria 
generates large mitochondrial networks that is beneficial in metabolic 
active cells and facilitates smoother oxidative phosphorylation capacity. 
In quiescent cells, mitochondria are instead present as small fragmented 
spheres or rods in response to fission [51]. However, an optimal function 
is maintained by having a balanced regulation of fusion and fission and 
dysfunction in this process is considered as a crucial factor in cardiac 
pathology [50]. Mitochondrial dysfunction is specifically associated 
with abnormal electron transport chain activity, reduced ATP 
production resulting in a shift in metabolic substrate utilization, reactive 
oxygen species (ROS) overproduction and impaired mitochondrial 
dynamics that will contribute to the development of different heart 
diseases [50, 52, 53].   
1.3.3 GLUCOSE UPTAKE AND UTILIZATION 
The heart is adapted to utilize all kinds of substrates to meet the high-
energy demands. Although FAs are known to be the predominant 
substrate in the heart during resting conditions, the heart is also having 
a basal glucose uptake and utilization. However, a prominent switch in 
substrate utilization towards glucose is induced during stressful 
conditions such as in response to ischemia or pathological hypertrophy 
[54-56].  
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Glucose uptake in cardiomyocytes is mediated by the glucose 
transporter isoforms GLUT1 and GLUT4. GLUT4 is the predominant 
GLUT isoform in the heart and it is regulated by insulin [55], and by 
cardiac contraction were its translocation to the plasma membrane in 
intracellular vesicles dependent on the work-load of the heart [56]. 
Therefore, GLUT4 transport and uptake is strongly regulated by 
environmental changes within the heart [54]. GLUT1 is found in the 
plasma membrane and regulates basal glucose uptake [54]. In addition, 
GLUT1 has been shown to be regulated by long-term fasting and 
chronic hypoxia that is mediated by hypoxia-inducible factor 1-α (HIF-
1α) involved in the response to low oxygen concentration within the 
body [57, 58]. When glucose is taken up in the cardiomyocytes it is 
rapidly phosphorylated into glucose 6-phospate (G6P) that can enter 
many different pathways. The major pathway G6P enters is glycolysis 
to generate pyruvate, NADH and ATP. In the cytosol, pyruvate can be 
converted to lactate, and if transported into the mitochondrial matrix, 
pyruvate undergoes oxidation to acetyl-CoA for the TCA-cycle [55, 59].  
 
A large number of studies has shown that transcriptional regulation of 
genes involved in mitochondrial oxidation are changed extensively 
during the progress towards pathological hypertrophy and HF [55]. 
Down-regulation of peroxisome proliferator-activated receptor α 
(PPARα) and proliferator-activated receptor gamma co-activator-1 
(PGC-1) which are master regulators of genes involved in FA oxidation 
has been observed. This impairment facilitates the increased AMP-
activated protein kinase (AMPK) activity that further promotes 
translocation of glucose transporters to the plasma membrane and 
enhanced glucose uptake and glycolysis. Nevertheless, studies have 
shown that increased glucose utilization is not harmful for the adult 
heart, but the reduced ability to utilize glucose might be detrimental in 
the diseased heart [58].  
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1.4 LIPIDS IN THE CELL 
Lipids are fundamental components of all cells, playing an important 
role in energy storage, cellular stabilization and signalling. Lipid 
composition differ in different tissues, cell types and in each organelle 
suggesting that different lipid compositions are required for different 
functions [60]. Lipids are components of cellular compartments such as 
plasma membrane, lipid droplets (LDs), nuclear membrane, 
endoplasmic reticulum (ER), Golgi apparatus and vesicles like 
endosomes and lysosomes [60]. The development in mass spectrometry 
has discovered that living cells consists of thousands of different lipids 
and through lipidomics we can now address the lipid distribution in 
different compartments [61].  
1.4.1 MEMBRANE LIPIDS 
Membrane lipids are amphipathic, meaning that they have a polar 
hydrophilic end and a non-polar hydrophobic end. In aqueous medium, 
membrane lipids do organize into bilayers with the polar ends oriented 
towards, and non-polar ends oriented away from the solution forming a 
membrane. There are three major classes of membrane lipids, which are; 
phospholipids, cholesterol and glycolipids, with phospholipids being the 
predominant membrane lipid [62, 63].  
1.4.2 PHOSPHOLIPIDS 
The major class of membrane lipids are phospholipids and they are 
abundant in all biological membranes. The structure of phospholipids 
consists of two hydrophobic FA tails and a hydrophilic head consisting 
of a phosphate group. Phospholipids can be built on a backbone of 
glycerol, carbon alcohol or on a sphingosine. These lipids facilitate the 
anchoring of proteins in the cell membrane and impact cellular shape. 
They are also essential for the regulation of exocytosis, endocytosis and 
chemotaxis [64]. There are four major phospholipids that are abundant 
in the plasma membrane of mammalian cells and they are; 
phosphatidylcholine (PC), phosphatidylethanolamine (PE), 
phosphatidylserine (PS) and sphingomyelin (SM) [65, 66].  
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1.4.3 CHOLESTEROL 
Cholesterol is structurally different from phospholipids and glycolipids 
and is built up from four linked hydrocarbon rings. A hydrocarbon tail 
is at one end of the steroid and a hydroxyl group is attached to the other 
end. The fused ring structure of cholesterol makes this lipid more robust 
than the other membrane lipids [66]. Cholesterol do regulate membrane 
fluidity, supply the body with fat and is involved in  synthesis of 
hormones [66]. Cholesterol is found with varying degree in different 
membranes. Almost 25% of membrane lipids in certain nerve cells are 
made up from cholesterol while in some intracellular membranes they 
are not present [67, 68].  
1.4.4 GLYCOLIPIDS 
Glycolipids are the sugar containing lipids that have one or more sugar 
attached to the backbone. These lipids are involved in regulating cell-
shape, fuel storage and are receptor components [63]. They do also serve 
as markers for cellular recognition thus facilitating cell-cell interactions 
[69].   
 
GLUCOSYLCERAMIDES 
Glucosylceramides (GlcCer) is the simplest form of glycolipids 
consisting of a ceramide with a sugar attached to it [69, 70]. The 
attachment of the sugar referred as glycosylation occurs by an enzyme 
called glucosylceramide synthase (GCS) that is encoded by the gene 
UGCG. GCS is localized to the Golgi apparatus and more specifically 
to the cis-Golgi site [69]. GlcCer is a precursor for over 300 species of 
glycosphingolipids, such as lactosylceramides (LacCer) that are 
important signaling molecules [71]. However, GlcCer must cross the 
lumen of the Golgi apparatus to be converted to higher order 
glycosphingolipids such as LacCer. GlcCer are involved in signal 
transduction, membrane trafficking, cytoskeletal organization and 
pathogen entry [72]. GlcCer together with cholesterol are further 
believed to be involved in the formation of lipid rafts and caveolae  
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structures within the plasma membrane involved in different signaling 
pathways [63, 73].  
 
Studies have shown that GlcCer is an absolutely essential lipid for the 
development of mammals, as mice lacking GlcCer do not survive due to 
embryonic lethality. However, to much GlcCer is also not beneficial 
reflected in Gauchers disease. This is the most common lysosomal 
storage disorder caused by a mutation in the gene for β-
glucocerebrosidase, which impairs or eliminates the enzyme that 
normally hydrolyses GlcCer to ceramide and glucose [74]. This results 
in excessive accumulation of GlcCer in different organs thus facilitating 
dysfunction in these tissues [75].  
1.4.5 LIPID DROPLETS 
Lipid droplets (LDs) are evolutionary conserved organelles found in 
almost all cell types from bacteria to mammals [76]. This dynamic 
organelle consists of a core of neutral lipids such as cholesterol esters 
(CE) and triglycerides (TG). The membrane that is surrounding the core 
consists of phospholipids, cholesterol and proteins with different 
function  with the major protein family being the perilipins (Plins) 
(Figure 2) [10, 76-79]. The formation of LDs is not completely 
elucidated and there are several theories on how LDs are formed. The 
most accepted theory is that they are formed de novo from ER in 
eukaryotes. It is believed that a lens of neutral lipids forms on the 
cytosolic side of the ER bilayer that buds of from the membrane. LDs 
seem to remain in contact with ER once they are formed, and proteins 
that associate with both organelles move between them [78, 80]. 
 
LDs store lipids that can be used as metabolic fuel, for membrane 
components,  post-translational protein modifications and signaling 
molecules within the cell [77, 80]. The energy status and nutrient 
availability within the cell controls whether the LD is expanding, 
shrinking, fusing or disappearing.  They can vary in size from 100 nm 
up to 100 µm in white adipose tissue (WAT) filling up the entire 
Ismena Mardani 
13 
adipocyte [10, 80]. Proteomic studies have shown that there is up to 200 
proteins that are being associated with LDs, some of which only exist 
on LDs while others are also found on other organelles such as ER, 
mitochondria and peroxisomes that are in close interaction with LDs 
[76, 81]. The proteins coating the LD can vary between droplets within 
the cell, between metabolic conditions and between cell types, and the 
limited capacity for proteins to bind on LDs further regulates this [77, 
80, 82]. Therefore, macromolecular crowding plays a major role in 
determining LD protein composition as proteins compete for binding to 
the surfaces of LDs. As such, LD binding affinity determines protein 
localization during LD expansion and shrinking [83]. Dysfunctional 
lipid storage within LDs has been associated with metabolic diseases 
such as obesity, type 2 diabetes (TD2), nonalcoholic fatty liver disease 
(NAFLD) and CVDs [82].  
 
 
 
Figure 2. Schematic drawing of LD. LD, Lipid droplet; CHOL, Cholesterol; PL, 
Phospholipid; Plin, Perilipin; TG, Triglyceride; CE, Cholesterol ester. 
1.4.6 TRIGLYCERIDE SYNTHESIS 
Triglycerides which is the major storage form of lipids in the LDs is 
composed of a glycerol backbone and three FAs. The FAs entering the 
cardiomyocytes can be activated and directly oxidized within 
mitochondria or they can be esterified and stored as TG. Most of the TG 
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pool is formed de novo within the cell through the glycerol phosphate 
pathway. De novo TG synthesis is initiated by acylation of glycerol-3-
phosphate (G3P) with a fatty acyl-CoA to generate lysophosphatidic 
acid (LPA). This is followed by further acylation and dephosphorylation 
yielding diglycerides (DGs). The last step to convert DGs to TGs is 
through acylation by DG acyltransferases (DGATs) within ER 
generating TGs, which is then stored in LDs. The catabolism of 
endogenous TG happens likely via the re-esterification of DGs derived 
from TG breakdown [84, 85]. 
 
1.5 PERILIPINS 
The most abundant protein family on LDs are the perilipins (Plins) and  
until now five different Plins are identified in mammals [81]. This 
protein family differs in size, binding affinity to LDs, stability when not 
bound to LDs, transcriptional regulation and tissue expression [77].  
 
More specifically, the Plin family, except for Plin4 is characterized by a 
sequence homology of a 100 amino acid region near the N-terminal end, 
defined as the PAT-domain. When first grouped as a family these 
proteins were named the “PAT” family after the first three Plin members 
identified: perilipin, adipocyte differentiation-related protein (ADRP) 
and tail-interacting protein of 47 kiloDaltons (TIP47). [82, 86]. This 
PAT domain is followed by a repeating 11-mer helical motif of varying 
length. Plin2, 3 and 5 are approximately 300-400 amino acids while 
Plin4 is 1500 amino acids because of an expanded 11-mer repeat region. 
Further, Plin1 has 4 splice variants containing the PAT region and 11-
mer helical motif but with different C-termini ends in mice [82, 87, 88]. 
Plin1, 4 and 5 have tissue-specific expression while Plin2 and 3 are 
ubiquitously expressed. In addition, Plin1 and Plin2 are only stable 
when bound to LDs while Plin3, 4 and 5 are stable on LDs but also in 
the cytoplasm (Table 1). Studies have shown that the major isoforms of 
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Plin1, 2 and 5 prefer to bind to LDs enriched in TGs while Plin4 prefer 
LDs enriched in CE [88-91].  
 
The main group of transcription factors (TF) that regulates Plins are the 
PPARs. There are three PPAR isoforms (α, β/δ and γ) that are activated 
by lipids and regulates lipid metabolism in various tissues. The heart has 
the highest expression of PPARα and all Plins except for Plin3 is 
regulated by these TFs within the heart [82, 91, 92].  
 
Table 1. Summary box about Plins 
Adipocyte differentiation-related protein, ADRP; Tail-interacting protein of 47 kDa, 
TIP47; Mannose-6-phosphate receptor-binding protein 1, M6PRBP1; Myocardial LD 
protein, MLDP; Lipid storage droplet protein 5, LSDP5; White adipose tissue, WAT; 
Brown adipose tissue, BAT; Lipid droplets, LDs. 
1.5.1 PERILIPIN 1 
Plin1 or perilipin, was the first Plin to be discovered and is mainly 
expressed in adipocytes of WAT and brown adipose tissue (BAT). It can 
also be detected in steroidogenic cells of the adrenal cortex, testis and 
ovaries [82]. Plin1 is essential for the regulation of lipolysis within the 
adipocytes, and is phosphorylated by protein kinase A (PKA) that is 
activated by insulin or noradrenaline. This specifically results in the 
phosphorylation of Plin1 and hormone sensitive lipase (HSL) and the 
release of comparative gene identification-58 (CGI-58) bound to Plin1, 
thus facilitating the interaction between the lipase ATGL and CGI-58 
and the onset of lipid hydrolysis [91, 93]. Lipolysis will result in the 
detachment of Plin1 from the LDs resulting in degradation by the 
proteasomal and lysosomal pathway [82, 94]. 
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Plin1 deficient mice has been generated creating a lean mouse model 
with an extensive reduction in adipose mass. This as a result of high 
basal lipolysis because the main Plin coating the LDs is Plin2. Plin2 has 
been shown to be less protective against lipases than Plin1 in adipose 
tissue [91, 95-97].  This does however protect the Plin1 deficient mice 
from weight gain associated with high-fat diet (HFD) [96].  
 
Even if Plin1 is not expressed within the heart, Plin1 deficiency is 
affecting heart physiology and function. Due to the high lipolysis which 
generates a high FA flux to the systemic circulation, ectopic lipid 
accumulation is generated within the heart. This results in increased β-
oxidation, ROS production and lipotoxicity that with time injuries the 
myocardial structure and thus the function. These mice do develop 
cardiac hypertrophy and ultimately  HF with time [98].  
 
In humans, Plin1 mutations are causing lipodystrophy syndrome, 
associated with hypertriglyceridemia, insulin-resistant and hepatic 
steatosis [99].  
1.5.2 PERILIPIN 2 
Plin2, also known as adipocyte differentiation-related protein (ADRP) 
and adiphophilin is the most abundant LD protein in non-adipose tissue. 
This Plin is mainly regulated by intracellular lipid accumulation [91, 
100]. Plin2 is stable when bound to LDs in presence of high lipid content 
but becomes degraded by the ubiquitin-proteasomal pathway under lipid 
poor conditions. Thus Plin2 and LDs provide a reciprocal stabilization 
[101-104]. Studies were Plin2 has been overexpressed in different cell-
lines and tissues results in induced LD accumulation while the opposite 
holds true for Plin2 deficiency [105-108]. 
 
More specifically, Plin2 deficient mice have a 60%  reduction of TGs in 
the liver and they are resistant to diet-induced obesity, fatty liver disease 
and alcohol induced steatosis [109-112]. Further, in a transgenic mice 
model with a cardiac-specific overexpression of Plin2 was cardiac 
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steatosis detected with accumulation of small LDs. This was suggested 
to be due to reduced activity of HSL suggesting that Plin2  might 
interfere with HSL [113]. 
 
Recent research on Plin2 has shown that overexpression of Plin2 
protects LDs against autophagy while Plin2 deficiency enhances 
autophagy resulting in depleted hepatic TGs levels [111]. This 
regulation seems to be initiated by the phosphorylation of Plin2 by 
AMPK enabling the binding of Plin2 with chaperone heat shock 70 kDa 
8 (HSPA8/Hsc70) facilitating degradation of Plin2 through chaperone 
mediated autophagy (CMA) and thus enabling lipophagy and lipolysis 
of LDs [114, 115].  
 
In humans, a missense polymorphism that has extensive effects on the 
protein structure and function of Plin2 has been identified. The 
individuals associated with this variant had lower TG and VLDL 
concentrations in the systemic circulation [100]. 
1.5.3 PERILIPIN 3 
Plin3 was initially called tail-interacting protein of 47 kDa (TIP47) or 
mannose-6-phosphate receptor-binding protein 1 (M6PRBP1) and was 
first discovered to be involved in intracellular trafficking of lysosomal 
enzymes [91, 116]. Later on, it was discovered that this protein has 
sequence similarities to Plin2. Plin3 is ubiquitously expressed and in 
contrast to Plin2 it is stable in the cytosol in addition to LDs [77]. 
 
Studies have shown that Plin2 and Plin3 are co-expressed and that Plin3 
can compensate for the lack of Plin2. However, in cell culture 
experiments does Plin3 have the least ability of all Plins to protect the 
LDs from lipolysis [117]. Recently, it has been shown that Plin3 is an 
AMPK substrate, and phosphorylation of Plin3 by AMPK promotes LD 
dispersion that might occur during starvation or AMPK activation [118]. 
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In addition, Plin3 is shown to be targeted for degradation by CMA 
together with Plin2 [115].   
1.5.4 PERILIPIN 4 
Plin4 or S3-12 is expressed primarily in fat storing tissues such at WAT 
and to a lesser degree in skeletal muscle and heart [119]. Plin4 has a 
unique structure due to the lack of the PAT domain but with a 
polypeptide length that is three-fold longer than the other Plins [91, 
120]. In adipocytes, Plin4 and Plin1 do coat different populations of 
LDs, and upon lipid loading is Plin4 coating new LDs and permits rapid 
packing of newly synthesized TGs [119].  
 
A Plin4 null mice has been generated but no major differences were seen 
in the lipid levels in adipose tissue. However, low TG levels were 
observed in the heart [120]. These mice did also have reduced Plin5 
mRNA and protein levels suggesting that Plin4 might regulate Plin5. 
The mice maintained a normal heart function and cardiac steatosis was 
prevented after HFD [120]. Nevertheless, these two genes are located 
close to each other in the mice genome and it has not been investigated 
whether the genetic manipulation of Plin4 could have impacted the 
expression of Plin5 and that these findings are due to alteration of Plin5 
and not Plin4.  
1.5.5 PERILIPIN 5 
First known as OXPAT, myocardial LD protein (MLDP) and lipid 
storage droplet protein 5 (LSDP5) but now as Plin5 is mainly detected 
in oxidative tissues such as heart, skeletal muscle and BAT [77, 86, 121]. 
Plin5 plays an important role for energy balance as it controls TG 
storage and lipolysis [121, 122]. The expression of Plin5 is increased 
within the heart upon response to FA exposure, such as during lipid-
loading conditions like fasting [82, 86, 123]. 
 
We and others have shown that Plin5 whole-body knockout mice have 
impaired TG storage within the heart. The mice can still maintain a 
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normal heart function due to increased glucose utilization during normal 
conditions [122, 124]. However, during dobutamine-induced stress, 
myocardial ischemia-reperfusion (I/R) injury and after MI, a severely 
reduced heart function and increased mortality was observed [124, 125]. 
We have further shown that Plin5 deficiency reduced mitochondrial 
oxidative capacity and that the lipid composition of the mitochondrial 
membrane is changed compromising mitochondrial membrane 
depolarization [126]. In contrary, two other groups have shown that 
heart-specific Plin5 overexpression within mice increases TG levels 
within the heart. This increase in TGs result in a decreased 
mitochondrial function, left ventricular hypertrophy but a maintained 
heart function [127, 128].  
 
At a molecular level, Plin5 is believed to act as a scaffolding protein 
against lipases. Cell studies have shown that Plin5 seem to bind to either 
ATGL or CGI-58 and block their interaction with each other thus 
inhibiting lipolysis. This blockage is broken when PKA becomes 
activated and phosphorylates Plin5 that releases itself from the enzymes 
facilitating lipolysis. However, the precise mechanism by which Plin5 
controls LD storage remains to be fully elucidated [86, 123, 129].  
 
Another cell-based study has shown that there is an association between 
Plin5 and mitochondria. Plin5 facilitates a physiological and metabolic 
linkage between LDs and mitochondria and directing FAs to LDs thus 
controlling the availability of FA for β-oxidation [86]. Recently, it has 
also been detected that Plin5 can induce transcription of genes in the 
nucleus by forming a complex with PGC-1α and sirtuin-1 (SIRT1) 
mediating mitochondrial biogenesis and oxidative function [130]. This 
study opens up for new possibilities that Plin5 might have more roles 
than just being a LD binding protein.  
 
1.6 AUTOPHAGY 
Autophagy is an evolutionary conserved and crucial process within the 
cells that facilitates the degradation of intracellular compartments such 
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as proteins, organelles, macromolecular complexes and pathogens [131-
133]. The formation of autophagosomes is thought to occur within the 
cytoplasm and is induced when a cup-shaped double-membrane 
structure is formed entitled a phagopore. It is not clear where this 
formation is started but it is suggested that the membrane source may 
involve contribution from the plasma membrane, ER and mitochondria 
[132]. When the phagopore is elongating it will start to engulf cellular 
material, and when it has surrounded its object, it is closing itself 
forming an autophagsome. The autophagsome is then moving on 
microtubules until it reaches a lysosome which it fuses with forming a 
structure called autolysosome. The lysosome consists of enzymes in an 
acidic environment enabling the degradation of the inner membrane of 
the autophagsome and the content within [134, 135]. This phenomenon 
is referred as macro-autophagy and is the most well-known autophagic 
pathway. There are in addition two other forms of autophagy named 
Microautophagy and Chaperone-mediated autophagy (CMA) (Figure 
3) [136, 137]. 
 
Microautophagy is the direct interaction of lysosomes with a substrate 
with an controlled invagination of lysosomal membranes and direct 
engulfment of a part of the substrate for degradation [76]. CMA is 
targeting specific proteins for degradation. The proteins contain a 
specific peptide sequence that signals for lysosomal degradation. This 
sequence is recognized by Hsc70 that delivers the substrate to lysosomes 
via lysosomal-associated membrane protein 2a (Lamp-2a) for 
degradation. [114, 136-140].  
 
Autophagy is divided into being selective and non-selective. Selective 
autophagy degrades protein aggregates, organelles, bacterial pathogens 
and signalling complexes that are detrimental and not utilized in the cell 
[141]. Non-selective autophagy is triggered by starvation and is 
important for the maintenance of a cellular supply of lipids, amino acids 
and nucleotides that are needed to provide energy and for the synthesis 
of new proteins [133, 142, 143].  A basal autophagy is ongoing 
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constantly and is very essential as a quality control mechanism thus 
facilitating proper cell physiology [132, 135, 141]. 
Proteins correlated with autophagy are the autophagy-related (ATG) 
proteins that are involved in the formation of autophagsomes. One of the 
proteins that has the strongest association with autophagosomes is 
microtubule-associated proteins 1A/1B light chain 3B or more 
commonly known as LC3B, which is a member of the ATG8 protein 
family. LC3B appears in two different form, LC3B-I and LC3B-II. 
LC3B-I is free in the cytosol were it becomes lipidated forming LC3B-
II, and thereafter translocate to autophagosomes were it seems to be 
involved in membrane expansion and fusion events and thus works as a 
good biomarker for autophagy [132, 135].  
 
One of the most known pathways regulating autophagy involves the 
serine/threonine kinase, mammalian target of rapamycin (mTOR). The 
induction of autophagy starts by the inhibition of mTOR under 
starvation conditions [132]. Many additional signals such as growth 
factors, amino acids, glucose, energy status and different forms of stress 
further regulates this pathway [133].  
1.6.1 LIPOPHAGY 
Lipophagy which is the degradation of LDs through autophagy is 
important for the breakdown of lipids to release free FA (FFA) and to 
maintain LD homeostasis and prevent lipotoxicity [140]. LDs can be 
degraded through macro-, microautophagy and CMA, explained in the 
autophagy section [80, 137, 138]. On LDs are both Plin2 and Plin3 
substrates for CMA degradation which enables macro- and 
microautophagy but also the recruitment of lipases such as ATGL to 
LDs for lipolysis [114, 138-140]. The induction of either autophagy or 
lipolysis for the degradation of lipids is tissue-specific. Lipolysis is the 
main option in adipose tissue that will result in a fast release of FAs as 
there is a high expression of lipases there. On the opposite, lipophagy is 
mainly induced in the liver due to low expression of lipases, thus 
facilitating a slower release of FAs  [140].  
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1.6.2 LIPASES AND LIPOLYSIS 
Lipolysis involves the hydrolysis of lipids to break free FAs in cells 
stored as TGs [144]. This process is regulated by the “lipolytic 
machinery” including adipose triglyceride lipase (ATGL), the ATGL 
activator comparative gene identification-58 (CGI-58), hormone 
sensitive-lipase (HSL) and monoglyceride lipase (MGL). ATGL 
initiates the rate-limiting step hydrolysing TG to DG and one FFA, while 
after HSL is performing the second step and hydrolyses DG to 
monoglyceride (MG) and one FFA. Lastly, MGL bind to MG and 
generates glycerol and one FFA [78, 80, 86, 144]. The FAs released 
from TGs in LDs have several fates. They can be used for β-oxidation 
to generate energy, used as building blocks for membrane lipids, work 
as co-factors for cell signalling or re-esterified into TGs [80]. Lipolysis 
is regulated by extracellular signals such as catecholamines and insulin 
but also by intracellular signals such as the levels of metabolites to 
balance the hydrolysis of FA with oxidative demands [14, 145]. 
Interestingly, it has also been proposed that there is an association 
between ATGL and autophagy/lipophagy. There seem to be a direct 
interaction between ATGL and LC3B on LDs, and that LC3B might 
play an important role for the translocation of ATGL to LDs, thus 
facilitating TG lipolysis within neurons [146]. In addition to this, ATGL 
is positively regulating SIRT1 within hepatocytes that is an activator of 
autophagy, thus promoting autophagy/lipophagy [147-149]. However, 
more thorough studies are needed to elucidate the crosstalk between 
lipases and the lipophagic machinery.  
  
Ismena Mardani 
23 
 
Figure 3. Schematic illustration of chaperone-mediated autophagy, microlipophagy, 
macrolipophagy and lipolysis. Hsc70, heat shock cognate 70 kDa protein; FFAs, free 
fatty acids.  
1.6.3 METABOLIC ADAPTATION IN CARDIAC 
DISEASE AND FAILURE 
To sum up, the normal heart derives most of its energy for contraction 
from the oxidation of FAs as previously mentioned. However, the heart 
adapts quickly to an acute or chronic change in its workload by oxidizing 
the most efficient fuel. The switch from one substrate to another is 
regulated by substrate availability, coronary blood flow, oxygen supply, 
circulating hormones and workload of the heart [150]. During a 
myocardial insult such as a MI is the heart switching to glucose as the 
main substrate, because glucose needs less oxygen than FA for the 
production of ATP [151]. The cardiac dysfunction and remodeling 
explained previously will promote metabolic abnormalities including 
reduced β-oxidation of lipids [7, 152], increased glucose uptake and 
accumulation of myocardial lipids [153-155]. It is well known that 
neutral lipids (TGs and CEs) accumulate in the failing heart [154, 155]. 
In addition, we have recently shown that sphingolipids (GlcCer) 
accumulate in the remodeling heart in response to an ischemic event 
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[154, 156]. Cardiac lipid accumulation is known to correlate with 
reduced heart function [157]. However, we do not know if this 
accumulation of lipids is detrimental or beneficial for the recovery of 
the heart. Therefore, we have focused on elucidating the role lipids plays 
within the healthy and diseased heart in this thesis.  
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2 METHODOLOGICAL CONSIDERATIONS 
In this section, considerations regarding selected methods are discussed. 
A more detailed description of all methods and materials are included in 
the enclosed papers.  
 
2.1 HUMAN MATERIAL 
To study lipid alterations and more specifically GlcCer levels in the 
remodeled heart, biopsies were taken from patients undergoing coronary 
artery bypass surgery due to atherosclerosis in the coronary vessels. A 
patient with an occluded vessel due to atherosclerosis has been exposed 
to injury as the obstruction of the blood flow is causing limited oxygen 
and substrate availability in that specific region of the heart, thus 
facilitates remodeling. Non-ischemic left ventricle control biopsies were 
obtained from patients that underwent aortic valve replacement, with 
angiography-verified absence of coronary artery disease in any major 
myocardial coronary artery branch. These patients have not been 
exposed to any extensive blockage in the blood flow that could induce 
ischemia and cell death. This facilitates the use of biopsies from 
seemingly healthy parts of the heart, without any remodeling. However, 
we cannot be completely sure that this condition does not affect the 
whole homeostasis of the heart. Yet, these control biopsies are the 
closest to physiologically normal as one would obtain, as it would be 
ethically not justifiable to take biopsies from completely healthy human 
hearts. It would in addition not be of relevance to take biopsies from a 
seemingly healthy part of the remodeled heart as it would not be 
comparable due to lipid level differences in different regions of the 
heart. 
 
2.2 MOUSE MODELS 
The use of animal models has for a long time been debated in the society. 
Nevertheless, the anatomical and physiological similarities between 
humans and specifically mice that shares a vast majority of the DNA has 
allowed us to study different molecular mechanisms and disease 
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conditions. This has further enabled researchers to test new treatment 
strategies in animal models before assessing it in humans.  
 
Mice have the advantage over other animal models as they are small and 
thus need small sized facilities that enables large scale studies cost-
efficiently. Mice do have a rapid turn-over rate and goes through birth 
to death much faster than larger animals, and female mice produce 
multiple litters per year. All this enables the study of different disease 
models much easier and faster [158]. The biggest advantage is the ability 
to produce different transgenic, knock-out and knock-in models 
resembling a variety of human diseases.  
 
However, we have to keep in mind that there is a considerable difference 
in size between humans and mice, that is immense and does affect 
different parameters. Mice have a much faster metabolism with more 
metabolic tissues such as BAT compared to humans [159]. Mouse cells 
have a denser mitochondrial organization compared to humans which is 
associated with a higher metabolic activity [159]. The higher metabolic 
activity in the mice will generate more reactive oxygen species (ROS) 
that is damaging for the cells and shortens lifespan [159, 160]. A big 
difference in the study of CVDs is that mice compared to humans carry 
much of its plasma cholesterol in high density lipoproteins (HDLs), 
while humans carry it as LDL. This results in that the non-genetically 
manipulated mice are resistant to the development of atherosclerosis in 
their arteries which further makes them less prone to develop CVDs 
[161].  
 
The human heart is in many ways similar to mice but there are some 
differences to consider. In addition to the size difference, the human 
heart beats on average between 60-80 beats per minute (bmp) while the 
mouse heart beats on average 400-600 bmp, indicating extensive 
differences in calcium handling and cardiac contraction [162]. The 
human heart is further resting on the diaphragm which is reflected in 
more pyramidal heart-shape morphologically. Mice on the other hand 
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which are four legged has a heart that is moving freely in the pericardial 
cavity resulting in a more rugby-shaped heart. The human atria are very 
prominent while in mice this structure is very small. In addition, the 
location of the coronary arteries is different between mice and humans. 
This results in that certain aspects are need to be considered when 
developing and studying different cardiac disease models within mice, 
and this is further discussed in section Myocardial infarction in mice 
[163, 164].  
 
2.3 IN VITRO MODEL SYSTEMS 
2.3.1 HL-1 CELLS 
HL-1 cells are a cardiomyocyte-like cell-line, derived from a mouse 
atrial tumor cell-line and has been extensively used in Paper III. These 
cells contract spontaneously in presence of noradrenaline (NA) in the 
medium. They have organized sarcomeres and express many genes 
similar to adult cardiomyocytes. HL-1 cells do maintain their phenotype 
after several passages and can be genetically manipulated with good 
efficiency compared to other cardiomyocyte-like cells and primary 
cardiomyocytes [165]. A disadvantage is that these cells are particular 
in their needs of a specific growth medium containing adenosine, NA 
and retinoic acid, in addition to a fibronectin-gelatin matrix to grow on, 
which limits the development of models of cardiac diseases [166, 167]. 
In our lab we have used HL-1 cells to elucidate the molecular 
mechanistic pathways that are affected by Ugcg depletion. This was set-
up by transfecting cells with Ugcg siRNA as this gene is expressed in 
these cells. A downside of using HL-1 cells in our lab is their low 
expression of Plin5 which has hindered us from studying LD 
metabolism in relation to Plin5.  
2.3.2 PRIMARY CARDIOMYOCYTES 
Primary cardiomyocytes isolated from the hearts of different mouse 
models have been used in all three papers, mainly to confirm that the 
findings are cardiomyocyte-specific. This has enabled the exclusion of 
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other cell-types in the heart that might interfere with the results. A 
disadvantage with this method is that the heart is taken out from its 
normal environment and the isolation of the cardiomyocytes is occurring 
in an abnormal setting that could have an impact on the response when 
performing the experiments. In addition, short-term experiments can 
only be performed due to the changes in the phenotype over time [168]. 
Nevertheless, this method is highly applied in our lab and the biological 
response when performing an experiment will be closer to an in vivo 
situation compared to any cardiomyocyte cell-line. Further, the control 
over the experimental conditions and settings makes this method very 
attractive for our studies. The primary cells are maintaining a normal 
cell morphology, and preserve many of their markers and function seen 
in vivo. Another essential characteristic of primary cells is the possibility 
to isolate from genetically manipulated mice were factors such as 
disease conditions but also age and sex can be considered when setting 
up the experimental model. This is very beneficial as we strive to 
develop personalized medicine and normal cell-lines cannot contribute 
with this setting [167].  
2.3.3 HEK293 CELLS 
In Paper III, we are using human embryonic kidney 293 (HEK293) cells 
as a model system. HEK293 cells are derived as the name states from 
human embryonic kidney and the cells are believed to be fibroblast-like. 
However, when characterizing the cells, it was discovered that they 
express abundantly neuron-specific genes, suggesting that this cell-line 
might actually be derived from an immature neuronal cell in the kidney. 
Nevertheless, these cells have been used for years in different contexts 
due to their stable growth and easy to genetically manipulate in terms of 
high transfection efficiency [169]. More specifically, HEK293 cells 
have been extensively used in the study of GPCRs [170]. 
 
In our lab, we have created a HEK293 system with stable overexpression 
of β1-AR for our aims in Paper III. We could see in primary 
cardiomyocytes isolated from the hUgcg-/- heart that they had a reduced 
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responsiveness when stimulating them with isoprenaline (ISO). 
However, we know that these mice develop dilated cardiomyopathy and 
die pre-mature, but we do not know when this remodeling is induced. It 
could be as early as in 8-weeks old mice, which is around the weeks that 
primary cardiomyocytes are isolated. By generating a HEK293 cell-line 
with a stable overexpression of β1-AR we are able to study the acute 
effect of Ugcg deletion through siRNA knockdown. This gives us the 
possibility to further study the role of GlcCer for receptor signaling.  
 
2.4 MODELS OF MYOCARDIAL DISEASE 
2.4.1 MYOCARDIAL INFARCTION IN MICE 
In order to evaluate how the heart is responding to pathological stress in 
the different mice models is MI induced in Paper I and II. This is done 
by ligating the left anterior descending (LAD) coronary artery which is 
the major vessel supplying the LV with blood. This procedure results in 
an infarction in an anterolateral and apical region of the LV and the 
injured area affects 40-60% of the heart. The injury is extensive but mice 
compared to humans can withstand the damage [171]. This disease 
model enables the study of myocardial changes such as remodeling over 
time within the heart.  
 
The anatomy of the coronary artery tree may slightly differ between 
different mouse strains, and one issue is that the LAD coronary artery is 
hard to detect and therefor a lot of practice is needed to be able to induce 
similarly sized infarction within the mice. In addition, the coronary 
artery tree of mice is different compared to humans and not 
characterized to the same extent as the human coronary vasculature. 
Mice do have two major coronary arteries, where the left coronary artery 
generally crosses over the left ventricle and gives off variable branches. 
A branch has been described as LAD because of its resemblance to the 
LAD in humans [163, 164, 172]. Further, the right coronary artery 
commonly divides immediately into two major branches supplying the 
right ventricle and septal region, thus the septum is saved from injury 
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during an infarction in mice. In humans, on the other hand is branches 
of the LAD coronary artery suppling the septum, and the remodeling of 
the heart will thus be different between the species in response to an 
injury [172, 173]. Further, the level, width and depth of the suture 
ligation has prominent effects on the MI size. Ligation higher up of the 
LAD coronary artery results in larger infarctions, but to high up can 
results in an increased mortality showing that small differences can have 
a big impact [174, 175]. In our lab, we are studying heart function and 
dimensions 24-hours post-MI to evaluate the acute response and around 
3-weeks post-MI to study the remodeling of the heart. This is done with 
ultrasound analysis which is a non-invasive method to evaluate cardiac 
morphology and function [176]. However, this procedure needs to be 
optimized due to the small size of the structure, the high HR and the 
need of sedation of the mice while still remaining a close to normal 
physiological state. 
 
Another issue to consider when using this disease model is that 
neovascularization is not observed in the adult mice heart after a MI 
compared to humans.  The lack of new blood vessel formation at the site 
of injury results in a much larger necrotic area with dead cardiomyocytes 
contributing to loss of cardiac regenerative capacity [177]. Within 
humans, the necrotic area is minimized due to newly forming blood 
vessels that can supply the area of damage with oxygen and substrates 
contributing to the formation of scar tissue rather than necrotic tissue. 
Therefore, even if the MI model in the mice is beneficial for the study 
of cardiac remodeling there are still some differences in the cardiac 
response between mice and humans. One might also suggest to study the 
response by inducing ischemia-reperfusion instead of a MI as this 
resembles more a human situation. However, by introducing reperfusion 
into the heart, a reperfusion injury is induced. We would thus not know 
if the reperfusion or the ischemia is causing the remodeling that we want 
to study, and therefore is the MI-model preferable used for our aims. 
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2.4.2 DOBUTAMINE- AND ISOPRENALINE-INDUCED 
STRESS 
For the assessment of cardiac response to acute stress is dobutamine 
used in all three papers. Dobutamine is a β1-adrenergic agonist of the 
heart that increases contractility and CO with minimal impact on blood 
pressure. An injection induces a rapid increase in HR and contractility 
enabling the study of how well the heart work in response to stress 
similar to an exercise on e.g. a treadmill [178].  
 
Isoprenaline (ISO) is a non-selective β-adrenergic agonist that is 
injected in mice over a time-course to induce cardiac remodeling and 
used in Paper III. This method is non-invasive and induces cardiac 
dysfunction, and depending on how many injections, dosage and times 
that are given, different degree of damage can be obtained. An acute 
model resembles stress-induced cardiomyopathy and a chronic model 
mimics advanced heart failure similar to humans [179].  
 
2.5 STATISTICAL ANALYSES 
The experimental results are presented as mean ± standard error of the 
mean (SEM) in all papers. All the statistical tests are used to test the null 
hypothesis. The null hypothesis propose that no statistical 
significance/difference exist e.g. between two experimental groups, and 
that it is true until statistical analysis proves otherwise [180, 181]. In our 
papers, statistical significance between groups was evaluated using 
unpaired two-tailed Student’s t test when two unmatched groups were 
compared. This test can be used when the samples are from a population 
following a normal distribution and is also referred as a parametric test. 
When a population cannot be assumed to be normally distributed a non-
parametric test is used, e.g. Mann-Whitney U-test [182]. Because we 
work with relatively small sample sizes it is not preferable to perform a 
normality test to test for normal distribution, as the results would be 
biased [183, 184]. However, it is assumed that most of the biological or 
physiological quantitative continuous variables approximately follow 
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normal distribution, and reach this with increasing sample size, and thus 
we use parametric tests for our statistical analyses [184, 185].  
 
When comparing three or more independent groups, a one-way 
ANOVA was used. However, this test only determines if there is a 
difference between two groups but do not determine between which of 
the groups. To be able to elucidate between which groups the differences 
exist, a post hoc test needs to be additionally done. This test should only 
be done if the one-way ANOVA test shows that indeed there is a 
significant difference. In Paper II we are using e.g. Bonferroni’s post 
hoc test, and this test suits when working with small sample sizes. In 
addition, a one-way ANOVA was used when one factor was considered 
such as genotype, but when there were more factors to consider like 
genotype and treatment, a two-way ANOVA was implemented followed 
by Bonferroni’s post hoc test. Further, In Paper III, we are additionally 
using Dunnett’s multiple comparisons test as we compare one control 
group to all the other experimental groups [186]. We are also analyzing 
the survival in our mouse models and have thus used the log-rank test 
that compares the survival between two or more groups. This test takes 
into account the whole survival time and not a specific time-point. In 
addition, this test does give all the events the same strength independent 
of the time at which the event happened. In comparison, other survival 
test can consider earlier events to have more strength [187].  
 
All the statistics were calculated in GraphPad prism, and a p-value <0.05 
was considered statistically significant. The p-value is used to determine 
if there is a significance of the results in correlation to the null-
hypothesis. The p-value can be between 0 and 1, and the smaller the 
value is, the higher probability that the null hypothesis can be rejected. 
If a p-value is 0.05, there is a 5% possibility that the null-hypothesis is 
true and that the results are by chance, but it does also mean that that 
there is a 95% possibility that the null-hypothesis can be rejected and 
we can accept an alternative hypothesis [180-182]. 
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3 AIMS 
 
The specific aims of the three papers included in this thesis are: 
 
Paper I. To investigate the role of Plin2 deficiency on myocardial 
lipid storage and utilization and the impact on heart
 function. 
 
Paper II. To elucidate if cardiac-specific overexpression of Plin5 is  
 beneficial for the heart function and survival post-MI. 
 
Paper III. To define the role of glucosylceramides in heart 
physiology and function. 
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4 RESULTS AND DISCUSSION  
 
Paper I: Plin2-deficiency reduces lipophagy and results in increased 
lipid accumulation in the heart 
 
In this study, we investigated the impact of Plin2 on myocardial lipid 
storage and cardiac function. Previous publication on Plin2 deficient 
mice has shown that these mice have lower hepatic TG levels and are 
protected against fatty liver disease and diet induced obesity, suggesting 
a beneficial role correlated with Plin2 deficiency [109]. In addition, 
cardiac-specific overexpression of Plin2 was associated with cardiac 
steatosis but without any adverse effects on cardiac function [113]. We 
therefore hypothesized that Plin2 deficiency would result in an opposite 
effect with a decreased amount of TG within the heart and possibly an 
improved heart function after MI. 
 
Unexpectedly, we did discover that Plin2-/- mice had increased 
myocardial TG levels within the heart and that this increase was 
cardiomyocyte-specific. This was not a result of disrupted mitochondrial 
biogenesis or respiration. Instead, we saw an increased protein 
expression of Plin3 and Plin5 which could be a compensatory effect, as 
shown in previous paper [188]. However, the cellular location was 
intriguing in the Plin2-/- cardiomyocytes. Plin3 was mostly coating LDs 
as expected but Plin5 was more prominent on vesicular structures close 
to the plasma membrane of the cardiomyocytes and not on LDs, which 
was not predicted. Previous studies have shown that Plin5 is abundant 
on cardiac LDs and strongly regulate lipid storage by working as a  
lipolytic barrier [122, 124, 127, 128, 189]. We therefore hypothesized 
that the increased amount of Plin5 was bound on the Plin2 deficient LDs 
and thus contribute to the increased TG levels by shielding the LDs. As 
we do not see an increased co-localization of Plin5 with LDs in the 
Plin2-/- mice hearts, it is not convincing to expect this. However, in 
addition to our unexpected finding another paper has detected Plin5 
within the nucleus were it works as a transcriptional regulator [130]. 
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Hence, this opens up for new questions of whether Plin5 but also other 
Plins have additional roles that just being LD-binding proteins, and more 
studies are needed to clarify this.   
 
To further elucidate why Plin2-/- mice have increased accumulation of 
TG, we investigated markers of lipophagy. Plin2 but also Plin3 has 
previously been shown to be substrates for CMA and therefore we 
hypothesized that this pathway might be affected [115]. Indeed, we saw 
a decrease of LC3BI/II in the Plin2 deficient cardiomyocytes and this 
was not caused by a higher autophagosomal turnover rate. In addition to 
this finding, we could confirm that there was a reduced co-localization 
of lysosomes with LDs suggesting that the lipophagic pathway is 
somehow affected. An increased accumulation of TG could be a result 
of a decrease in CMA targets, which Plin2 is. The lack of Plin2 might 
make it more difficult for the CMA machinery to attach on LDs.  This 
could result in that the LD remains protected and that 
autophagy/lipophagy is blocked. On the other hand, we do see more 
Plin3 on the Plin2 deficient LDs which is also believed to be a target for 
CMA and theoretically would facilitate CMA. However, Plin2 might be 
more prone for CMA degradation than Plin3, but this needs to be further 
elucidated.  
 
Interestingly, TG levels were also higher in the cardiomyocyte-specific 
Plin2 overexpressing mice but as a result of a reduced HSL activity 
[113]. In our model we have not investigated the activity of lipases but 
if CMA is blocked it would theoretically also hinder the attachment of 
lipases. However, within the liver Plin2 overexpression is correlated 
with an inhibited autophagy and the opposite holds true for Plin2 
deficiency, which is opposite to what we see within the heart [111]. 
Thus, our finding suggests that CMA and autophagy/lipophagy is very 
much tissue-specifically regulated and that the ratio of the different 
proteins coating LDs probably strongly influences LD catabolism, and 
thus heart function during normal condition but also in response to 
pathological stress.  
Cardiac lipids and their role in the diseased heart 
36 
Paper II: Cardiac-specific overexpression of perilipin 5 promotes 
physiological hypertrophic remodeling of the heart by fine-tuning 
calcium-handling regulators 
 
We have previously shown that mice deficient in Plin5 have an altered 
substrate utilization that affects heart function during stress and 
myocardial ischemia, leading to increased mortality [124]. Therefore, 
we hypothesized that overexpression of Plin5 within the heart might be 
favorable for the outcome after a MI. We generated MHC-Plin5 mice, 
with heart-specific overexpression of Plin5. Lipid analysis revealed that 
MHC-Plin5 mice have an increased content of TG within the heart, in 
agreement with previous published papers on models with heart-specific 
overexpression of Plin5 [127, 128]. 
 
We then assessed heart function with echocardiography that showed an 
increased LV mass in MHC-Plin5 compared to WT mice hearts, without 
affecting heart function during baseline conditions similarly to previous 
publication [127]. Through further characterization we could detect an 
increase in cardiomyocytes size indicating a form of hypertrophy 
without any adverse remodelling or fibrosis. Therefore, we decided to 
identify if it is a pathological or physiological hypertrophic growth 
induced in the cardiomyocytes. A diseased heart with pathological 
hypertrophy typically has a re-activation of the fetal gene program with 
a prominent upregulation of natriuretic peptides [38, 190]. We could 
detect a downregulation in ANP expression and no difference in BNP 
expression. In addition to this, we found a downregulation of 
pathological hypertrophy markers but more interestingly, the 
PI3K/AKT/mTOR pathway usually upregulated during physiological 
hypertrophy was not activated [39]. This implies that the mice do have 
a phenotype similar to physiological hypertrophy without the induction 
through exercise such as wheel running or swimming [191], nor through 
the activation of the usual signalling pathway upregulated during 
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physiological hypertrophy. The MHC-Plin5 mice thus have a phenotype 
that is induced through a pathway not identified yet.  
In addition to this, physiological hypertrophy is further characterized by 
a maintained or improved heart function that do not promote the 
development of dilated cardiomyopathy and HF [38]. As physiological 
hypertrophy is beneficial for heart function, we decided to induce 
pathological stress to see how the MHC-Plin5 hearts persist these 
conditions. The mice showed to have similar heart function with a 
maintained SV and CO but with a prominently lower pulse after MI, 
suggesting that the MHC-Plin5 hearts might have better cardiac 
contractility. When investigating markers for cardiac contraction, we 
could identify an increased CamKII activity that is a prominent regulator 
of SERCA2a and Ca2+ flow implying that this pathway might be 
changed. However, more thorough studies are needed to evaluate the 
exact mechanistic behind the increased CamKII activity. This, 
specifically since CamKII is involved in many other transmembrane 
electrical processes and its upregulation is in contradiction to our study 
associated with heart diseases and not with an improved heart function 
[192, 193].  
 
Comparing the Plin2-/- vs. the MHC-Plin5 mice 
We have been elucidating the role of lipid metabolism within the heart 
for heart physiology and function by using two mouse models with 
differences in their perilipin expression. Both models result in an 
increased amount of TGs within the heart and both models do have more 
Plin5. However, the Plin2 deficient model have a reduced heart function 
in response to MI, while the MHC-Plin5 model seem to resist this stress 
even with a hypertrophic heart. The major difference in relation to LD 
proteins is that one model lacks Plin2 and the other model express Plin2. 
We show that Plin2 deficiency seem to affect substrate availability 
possibly by hindering CMA and consequently autophagy/lipophagy, 
thus affecting heart function in response to stress. Therefore, we 
speculate that the major differences we see between these models is 
because of different perilipin distribution on the LDs but also within the 
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cell. Even if both mice models have more Plin5, the increased 
expression does not seem to affect substrate availability. The Plin5 
lipolytic barrier is known to be broken during conditions such as fasting  
within the heart [189]. Hence, if it exists in these mice it is probably also 
broken during more extensive stress such as MI. Further, we have not 
completely characterized if Plin5 is the major perilipin coating the LDs 
in the MHC-Plin5 mice. Maybe the excessive amount of Plin5 is serving 
additional functions and is not extensively localized to LDs, such as 
surprisingly seen in the Plin2-/- mice. As our results suggest that 
overexpression of Plin5 affects cardiac contractility but also the 
initiation of physiological hypertrophy, it implies once again that Plin5 
participates in other signaling pathways also in the MHC-Plin5 mice.  
 
Paper III: Cardiomyocyte-specific deficiency in glucosylceramide 
synthase results in dilated cardiomyopathy and premature death in 
mice 
 
GlcCer are important structural components of cellular membranes, but 
they are also involved in numerous cellular processes, such as 
proliferation and differentiation [194, 195]. We have previously shown 
that ceramides [156] but now also GlcCer levels correlate with heart 
function in the remodeling human heart following ischemia. In addition, 
we could translate these findings into mouse models where cardiac 
remodeling was induced and where we could detect altered GlcCer 
levels. Therefore, we generated mice with cardiomyocyte-specific 
deficiency in glucosylceramide synthase (hUgcg–/– mice) to elucidate 
the role of GlcCer for heart physiology and function. These mice were 
born and developed normally to adulthood together with a maintained 
heart morphology, even with reduced GlcCer levels in the 
cardiomyocytes. Heart function was preserved in young mice during 
baseline conditions but when exposed to stress, a decrease in systolic 
function was detected. In addition to this, all the hUgcg-/- mice died 
premature by the age of 40 weeks due to dilated cardiomyopathy. To 
clarify what is causing the development of dilated cardiomyopathy, 
ultrastructure of the cardiomyocytes were investigated. Swollen Golgi 
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apparatus structures were identified and this is believed to affect the 
autophagic and endolysosomal pathway [196, 197]. We could confirm 
an abnormal pattern with autophagic and lysosomal vesicles close to the 
plasma membrane. In addition, we detected lower levels of LC3B, 
which was not caused by an increased autophagic flux but instead by a 
decreased induction of autophagy through the mTOR pathway.  
 
Further, as GlcCer are membrane lipids that are thought to be involved 
in structures such as lipid rafts and caveolae it is ideal to think that 
alterations in GlcCer levels can impact receptors on the plasma 
membrane. In agreement with this, we observed impaired cardiac 
contraction in response to stress, and we speculated whether the β-AR 
receptor signaling pathway might be affected. This was confirmed by 
detecting a reduced responsiveness when stimulating the Ugcg deficient 
cardiomyocytes with ISO.  Thus, our findings show that GlcCer are 
fundamental for normal heart physiology and function. Absence of this 
membrane lipid result in mice that die premature due to dilated 
cardiomyopathy. This is a combined effect of alterations in the Golgi 
structure, autophagy and endolysosomal regulation that further results 
in a disrupted β-AR signaling.  
 
However, some aspects to consider regarding this model is that we are 
additionally using cell systems to confirm that the alterations we see 
indeed is due to Ugcg deficiency and not that the cardiomyocytes are 
already diseased, because we do not know when the maladaptation 
starts. The cell systems are excellent ways to further elucidate the 
molecular pathways but they cannot completely replicate an in vivo 
situation. It would therefore be valuable to create a mouse model where 
an acute Ugcg deficiency could be induced that would more precise 
pinpoint which pathways that are truly affected by the absence of 
GlcCer. Another limitation is that there is a significant decrease in 
LacCer levels, which is a lipid species downstream of GlcCer. For now, 
we do not know whether all the alterations are because of GlcCer 
depletion or if some could be an effect of LacCer deficiency. To be able 
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to elucidate which lipid species that gives which specific phenotype, 
generation of a cardiomyocyte-specific lactosylceramide synthase 
(LCS) deficient mice model could be a strategy. 
 
Remodeling the cardiac lipid composition 
In all three papers we have altered the lipid composition within the heart. 
It is clearly shown that the absence of the membrane lipid GlcCer seem 
to give the most detrimental phenotype. This is not surprising as GlcCer 
are fundamental components of the plasma membrane thus affecting 
many different cellular pathways within the cardiomyocytes. Thus, our 
results imply that it is important with GlcCer within the heart and that 
the increased accumulation of this membrane lipid in mice models of 
cardiac remodeling in addition to the diseased human heart, do not 
necessary need to correlate with being detrimental. The accumulation of 
GlcCer might be beneficial to facilitate a proper remodeling and 
recovery of the heart, but more studies are needed to clarify this.  
 
In addition, we show that increased TGs levels in the Plin2-/- and MHC-
Plin5 mice do not give a harmful phenotype unless exposed to 
pathological stress, such as seen in the Plin2-/- mice. It does further not 
seem to be the increase in TGs that is damaging for the heart, but rather 
the inability to utilize the substrate in a sufficient way. Many studies do 
imply that increased cardiac lipid accumulation is causing heart 
dysfunction or exacerbates heart diseases specifically in obese or 
diabetic patients due to increased lipotoxicity [8, 13]. However, from 
our studies we clearly show that this is not always the case. Hence, an 
overall insight to consider is that an increased lipid accumulation does 
not always have to correlate with heart dysfunction.  
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5 CONCLUSIONS 
 
We conclude that: 
 
Paper I 
Plin2 regulates cellular lipid metabolism in a tissue-specific manner. In 
cardiomyocytes, Plin2 deficiency results in increased lipid accumulation 
as a result of reduced lipophagy.  
 
Paper II 
Overexpression of Plin5 within cardiomyocytes results in physiological 
hypertrophy, with improved cardiomyocyte contractility and calcium 
handling.  
 
Paper III 
The sphingolipid GlcCer accumulate in human heart following injury. 
Ugcg deficiency in cardiomyocytes results in Golgi dispersion, 
abnormal autophagic regulation causing a compromised β-AR 
signaling, leading to dilated cardiomyopathy and premature death in 
mice. 
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6 FUTURE PERSPECTIVES 
 
In this thesis, I have studied and provided insight into the role of cardiac 
lipid composition for heart physiology and function. However, our 
studies open up for several unanswered questions. 
 
We still do not know whether it is the elevated levels of Plin3 and/or 
Plin5, or if it is the deficiency in Plin2, that affects the lipophagic 
machinery in the Plin2-/- mice in Paper I. To address this question, we 
can create additional cell systems/ mouse models. We do have mouse 
embryonic fibroblasts (MEFs) isolated from Plin2-/- and WT mice where 
we could ideally overexpress Plin3 and/or Plin5 to see if a similar 
phenotype could be simulated. This would contribute with further 
information on which perilipins that regulates or are regulated by 
CMA/lipophagy and clarify substrate availability in relation to perilipins 
coating the LDs. These findings would increase the knowledge on how 
lipids are stored within the heart and how lipophagy is regulated within 
the cardiomyocytes.   
 
In Paper II, we show that elevated expression of Plin5 is beneficial for 
cardiac function. It would be interesting to cross-breed MHC-Plin5 mice 
into different pathological heart disease mouse models and see if the 
heart function is improved or rescued. These results would indicate 
whether a potential treatment strategy could be to induce increased 
cardiac expression of Plin5 in patients with a compromised heart 
function. Because direct delivery of Plin5 to cardiac tissue would be 
challenging, one way would be to increase transcription of Plin5. To 
date, Plin5 is known to be regulated by fasting [121] through the 
transcription factor C/EBPα [198], in addition to PPARα [121]. Thus, a 
potential way of targeting Plin5 is via C/EBPα or PPARα. 
 
In addition, RNA-sequencing analysis would also give more 
information on pathways that are affected in the MHC-Plin5 mice, 
enabling us to further dissect and clarify how our phenotype is induced.  
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In Paper III, we show that reduced levels of GlcCer and expression of 
cardiac Ugcg results in severe heart failure. I would like to investigate 
whether reduced levels of GlcCer and/or gene expression of Ugcg in the 
heart is a clinically relevant situation. One way to address this question 
would be to test if genetic variation of genes involved in sphingolipid 
synthesis may predispose to dilated cardiomyopathy.  
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